MA71698A - Compositions pour le traitement de maladies médiées par cftr - Google Patents
Compositions pour le traitement de maladies médiées par cftrInfo
- Publication number
- MA71698A MA71698A MA71698A MA71698A MA71698A MA 71698 A MA71698 A MA 71698A MA 71698 A MA71698 A MA 71698A MA 71698 A MA71698 A MA 71698A MA 71698 A MA71698 A MA 71698A
- Authority
- MA
- Morocco
- Prior art keywords
- cftr
- compositions
- treatment
- mediated diseases
- mediated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263395048P | 2022-08-04 | 2022-08-04 | |
| PCT/US2023/071721 WO2024031081A1 (fr) | 2022-08-04 | 2023-08-04 | Compositions pour le traitement de maladies médiées par cftr |
| EP23762115.6A EP4565212A1 (fr) | 2022-08-04 | 2023-08-04 | Compositions pour le traitement de maladies médiées par cftr |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA71698A true MA71698A (fr) | 2025-05-30 |
Family
ID=87847869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA71698A MA71698A (fr) | 2022-08-04 | 2023-08-04 | Compositions pour le traitement de maladies médiées par cftr |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4565212A1 (fr) |
| AU (1) | AU2023320558A1 (fr) |
| CL (1) | CL2025000244A1 (fr) |
| CO (1) | CO2025001274A2 (fr) |
| MA (1) | MA71698A (fr) |
| MX (1) | MX2025000710A (fr) |
| WO (1) | WO2024031081A1 (fr) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020017295A1 (en) | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
| US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| PL374442A1 (en) | 2001-11-14 | 2005-10-17 | Teva Pharmaceutical Industries Ltd. | Amorphous and crystalline forms of losartan potassium and process for their preparation |
| HUE032540T2 (en) | 2004-06-24 | 2017-09-28 | Vertex Pharma | Modulators of ATP-binding cassette transporters |
| CA2635581C (fr) | 2005-12-28 | 2017-02-28 | Vertex Pharmaceuticals Incorporated | Formes solides de n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoleine-3-carboxamide |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| CN102231990B (zh) | 2008-08-13 | 2013-09-25 | 沃泰克斯药物股份有限公司 | N-[2,4-双(1,1-二甲基乙基)-5-羟基苯基]-1,4-二氢-4-氧代喹啉-3-甲酰胺的药物组合物和其给药 |
| RU2711481C2 (ru) | 2010-03-25 | 2020-01-17 | Вертекс Фармасьютикалз Инкорпорейтед | ТВЕРДЫЕ ФОРМЫ (R)-1-(2, 2-ДИФТОРБЕНЗО[d][1, 3]ДИОКСОЛ-5-ИЛ)-N-(1-(2, 3-ДИГИДРОКСИПРОПИЛ)-6-ФТОР-2-(1-ГИДРОКСИ-2-МЕТИЛПРОПАН-2-ИЛ)-1H-ИНДОЛ-5-ИЛ)ЦИКЛОПРОПАНКАРБОКСАМИДА |
| RU2692779C2 (ru) | 2012-02-27 | 2019-06-27 | Вертекс Фармасьютикалз Инкорпорейтед | Фармацевтическая композиция и ее введения |
| CA2944140C (fr) | 2014-04-15 | 2022-10-04 | Vertex Pharmaceuticals Incorporated | Compositions pharmaceutiques destinees au traitement des maladies liees au regulateur de la conductance transmembranaire de la mucoviscidose |
| JOP20190125B1 (ar) | 2016-12-09 | 2022-03-14 | Vertex Pharma | مُعدِّل لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل |
| AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| TWI810243B (zh) * | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| WO2020242935A1 (fr) * | 2019-05-29 | 2020-12-03 | Vertex Pharmaceuticals Incorporated | Méthodes de traitement de la mucoviscidose |
-
2023
- 2023-08-04 MA MA71698A patent/MA71698A/fr unknown
- 2023-08-04 AU AU2023320558A patent/AU2023320558A1/en active Pending
- 2023-08-04 WO PCT/US2023/071721 patent/WO2024031081A1/fr not_active Ceased
- 2023-08-04 EP EP23762115.6A patent/EP4565212A1/fr active Pending
-
2025
- 2025-01-17 MX MX2025000710A patent/MX2025000710A/es unknown
- 2025-01-27 CL CL2025000244A patent/CL2025000244A1/es unknown
- 2025-02-04 CO CONC2025/0001274A patent/CO2025001274A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4565212A1 (fr) | 2025-06-11 |
| AU2023320558A1 (en) | 2025-01-23 |
| WO2024031081A1 (fr) | 2024-02-08 |
| MX2025000710A (es) | 2025-03-07 |
| CL2025000244A1 (es) | 2025-04-11 |
| CO2025001274A2 (es) | 2025-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3976189C0 (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA51200A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| EP3866781A4 (fr) | Nouvelles compositions pour le traitement de maladies inflammatoires | |
| MA52873A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA51739A (fr) | Compositions pharmaceutiques pour le traitement de la fibrose kystique | |
| EP3937932A4 (fr) | Inhibiteurs de cgaz pour le traitement de maladies auto-inflammatoires et de métastases cancéreuses | |
| EP3946357A4 (fr) | Formulations topiques pour le traitement de neuropathies périphériques | |
| EP3890747A4 (fr) | Compositions pour le traitement de la fibrose et de l'inflammation | |
| EP4045036A4 (fr) | Amides hétéroaryle-biphényle pour le traitement de maladies associées à pd-l1 | |
| EP3829569A4 (fr) | Formulations de spinosyne pour le traitement de maladies oculaires et faciaux provoquées par demodex | |
| MA55497A (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoires | |
| MA50391A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires | |
| MA55604A (fr) | Dérivés de pyrrolotriazine pour le traitement de maladies médiées par kit et pdgfra | |
| MA55218A (fr) | Eskétamine pour le traitement de la dépression | |
| EP3781584A4 (fr) | Promédicaments de 4'-thio-nucléotide et de nucléoside pour le traitement du cancer | |
| MA52941A (fr) | Dérivés de thiophène pour le traitement de troubles provoqués par ige | |
| MA53614A (fr) | Protéine pour le traitement de maladies inflammatoires | |
| MA55982A (fr) | Composition pharmaceutique pour le traitement de tumeurs | |
| EP4395753A4 (fr) | Fenfluramine pour le traitement de maladies et d'affections démyélinisantes | |
| EP3936124A4 (fr) | Composition pharmaceutique pour la prévention ou le traitement de maladies neurologiques | |
| EP4209216A4 (fr) | Composition pharmaceutique pour le traitement de tumeurs | |
| MA54873A (fr) | Compositions et méthodes pour le traitement de troubles neurocognitifs | |
| EP4228655C0 (fr) | Dérivés de tétracycline pour le traitement de maladies neurodégénératives ou neuro-inflammatoires | |
| MA71698A (fr) | Compositions pour le traitement de maladies médiées par cftr | |
| EP4247415A4 (fr) | Composition pharmaceutique pour le traitement de maladies du foie à utilisant la ssu72 |